上市小分子抗病毒药物研究进展

薛圣志, 毕金龙, 惠新平, 武全香

Research Progress of Commercial Small-Molecule Antiviral Drugs

Shengzhi Xue, Jinlong Bi, Xin-Ping Hui, Quan-Xiang Wu

表2 31、34和35对C8166细胞RT耐药株的抗HIV-1活性a [23]

HIV strain 31 34 35 EC50/(nmol∙L−1) FC b EC50/(nmol∙L−1) FC EC50/(nmol∙L−1) FC Wild type HIV-1IIIB 0.11 ± 0.02 1 201.89 ± 34.11 1 9.39 ± 1.22 1 FNCP-21 HIV-1IIIB 80.82 ± 8.14 735 123,690 ± 18,321 613 12.29 ± 0.24 1.31 3TCP-21 HIV-1IIIB 25.49 ± 1.86 232 690,210 ± 64,066 3419 13.13 ± 2.43 1.40 HIVLAI-M184V 27.45 ± 2.85 250 > 800,000 > 3963 8.21 ± 1.30 0.87